PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (IMMUNE SUPPORT)
DRUG NAME: THYMOSIN ALPHA-1

  • FDA Safety Data Sheet not available (experimental peptide therapy).

  • Dinetz E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024 [PubMed Link]

  • Dominari A. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020 [PubMed Link]

  • Cao A. Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. J Coll Physicians Surg Pak. 2024 [PubMed Link]

  • Wei Y. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. Int Immunopharmacol. 2023 [PubMed Link]

  • Soeroto AY. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023 [PubMed Link]

  • Garaci E. Phenotypic drug discovery: a case for thymosin alpha-1. Front Med (Lausanne). 2024 [PubMed Link]

  • Tian Y. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol. 2025 [PubMed Link]

  • Mao L. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. Int Immunopharmacol. 2023 [PubMed Link]

  • Minutolo A. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. Int Immunopharmacol. 2023 [PubMed Link]

  • Bellet MM. Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. Eur J Med Chem. 2021 [PubMed Link]

  • Peng D. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2020 [PubMed Link]

  • Liu Y. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020 [PubMed Link]

  • Solmonese L. The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. Onco Targets Ther. 2025 [PubMed Link]